Economic evaluation of pneumococcal conjugate vaccination in The Gambia

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Kim, Sun Young ^a   Lee, Gene ^a   Goldie, Sue J ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Harvard Initiative for Global Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

ARTICLE; BACTERIAL PNEUMONIA; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EPIDEMIOLOGICAL DATA; FATALITY; GAMBIA; HEALTH CARE COST; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; PNEUMOCOCCAL INFECTION; SENSITIVITY ANALYSIS; SEROTYPE; VACCINATION; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGY; INFANT; NEWBORN; PRESCHOOL CHILD;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GAMBIA; HUMANS; INFANT; INFANT, NEWBORN; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION; VACCINES, CONJUGATE;

EID: 77957128544     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-260     Document Type: Article

References (76)

1. WHO The Global Burden of Disease: 2004 Update. Geneva 2008, WHO., http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html
2. CDC Progress in Introduction of Pneumococcal Conjugate Vaccine-Worldwide, 2000-2008. MMWR Weekly 2008, 57(42):1148-1151. CDC.
3. Scott J. The preventable burden of pneumococcal disease in the developing world. Vaccine 2007, 25:2398-2405. 10.1016/j.vaccine.2006.09.008, 17028081.
4. Mulholland K. Childhood pneumonia mortality--a permanent global emergency. Lancet 2007, 370(9583):285-9. 10.1016/S0140-6736(07)61130-1, 17658399.
5. O'Dempsey TJ, McArdle TF, Lloyd-Evans N, Baldeh I, Laurence BE, Secka O, Greenwood BM. Importance of enteric bacteria as a cause of pneumonia, meningitis, and septicemia among children in a rural community in The Gambia, West Africa. Pediatr Infect Dis J 1994, 13(2):122-128. 10.1097/00006454-199402000-00009, 8190537.
6. Yamanaka N, Hotomi M, Billal D. Clinical bacteriology and immunology in acute otitis media in children. J Infect Chemother 2008, 14:180-187. 10.1007/s10156-007-0599-3, 18574652.
7. Dagan R. New insights on pneumococcal disease: What we have learned over the past decade. Vaccine 2009, 27(Suppl 3):C3-5. 10.1016/j.vaccine.2009.06.002, 19552985.
8. Cutts FT, Zaman SM, Enwere G, Jaffar S, Levine OS, Okoko JB, Oluwalana C, Vaughan A, Obaro SK, Leach A, McAdam KP, Biney E, Saaka M, Onwuchekwa U, Yallop F, Pierce NF, Greenwood BM, Adegbola RA, . Gambian Pneumococcal Vaccine Trial Group Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 2005, 365:1139-1146. 10.1016/S0140-6736(05)71876-6, 15794968, Gambian Pneumococcal Vaccine Trial Group.
9. Enwere G, Cheung YB, Zaman SM, Akano A, Oluwalana C, Brown O, Vaughan A, Adegbola R, Greenwood B, Cutts F. Epidemiology and clinical features of pneumonia according to radiographic findings in Gambian children. Tropical Medicine and International Health 2007, 12(11):1377-1385. 10.1111/j.1365-3156.2007.01922.x, 18045264.
10. Saaka M, Okoko BJ, Kohberger RC, Jaffar S, Enwere G, Biney EE, Oluwalana C, Vaughan A, Zaman SM, Asthon L, Goldblatt D, Greenwood BM, Cutts FT, Adegbola RA. Immunogenicity and serotype-specific efficacy of a 9-valent pneumococcal conjugate vaccine (PCV-9) determined during an efficacy trial in The Gambia. Vaccine 2008, 26(29-30):3719-3726. 10.1016/j.vaccine.2008.04.066, 18514974.
11. Madhi SA, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25(13):2451-2457. 10.1016/j.vaccine.2006.09.019, 17023095.
12. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, . Vaccine Trialists Group A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003, 349(14):1341-1348. 10.1056/NEJMoa035060, 14523142, Vaccine Trialists Group.
13. Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009, 8(11):1479-1500. 10.1586/erv.09.113, 19863240.
14. Lifesciences world New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease. Lifesciences world., http://www.lifesciencesworld.com/life-science-news/view/108502
15. WHO Worldwide progress in introducing pneumococcal conjugate vaccine, 2000-2008. Weekly Epidemiological Record 2008, 83(43):388-92. WHO.
16. GAVI Alliance Approved Support-Pneumococcal Vaccine. GAVI Alliance., http://www.gavialliance.org/performance/commitments/pneumococcal/index.php
17. Donor Working Group Framework Document: Pilot AMC for Pneumococcal Vaccines. Donor Working Group., http://www.vaccineamc.org/files/Framework%20Pneumo%20AMC%20Pilot.pdf
18. World Bank Ministers of Finance And Global Health Leaders Fulfill Promise to Combat World's Greatest Vaccine-Preventable Killer of Children. World Bank., http://web.worldbank.org/WBSITE/EXTERNAL/NEWS/0,,contentMDK:22210869~pagePK:64257043~piPK:437376~theSitePK:4607,00.html
19. World Bank World Development Indicators 2008. Washington 2008, World Bank., http://data.worldbank.org/indicator
20. WHO World Health Statistics. Geneva 2008, WHO.
21. GAVI Alliance Policy Brief: GAVI Alliance New Vaccine Co-financing Policy. GAVI Alliance., http://www.gavialliance.org/resources/GAVI_co_financing_policy_brief_Aug2008.doc
22. Shepard DS, Walsh JA, Kleinau E, Stansfi eld S, Bhalotra S. Setting priorities for the Children's Vaccine Initiative: a cost-effectiveness approach. Vaccine 1995, 13:707-714. 10.1016/0264-410X(94)00063-S, 7483785.
23. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus infl uenzae type b, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Econ 2000, 9:19-35. 10.1002/(SICI)1099-1050(200001)9:1<19::AID-HEC487>3.0.CO;2-C, 10694757.
24. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389-96. 10.1016/S0140-6736(07)60195-0, 17276779.
25. WHO Pneumonia Vaccine Trialists Group Standardization of Interpretation of Chest Radiographs for the Diagnosis of Pneumonia in Children. WHO Department of Vaccines and Biologicals. WHO/V&B/01.35. 2001, WHO Pneumonia Vaccine Trialists Group.
26. Cherian T, Mulholland EK, Carlin JB, Ostensen H, Amin R, de Campo M, Greenberg D, Lagos R, Lucero M, Madhi SA, O'Brien KL, Obaro S, Steinhoff MC. Standardized interpretation of paediatric chest radiographs for the diagnosis of pneumonia in epidemiological studies. Bull World Health Organ 2005, 83(5):353-9. 2626240, 15976876.
27. GAVI Alliance Rwanda becomes first developing nation to introduce vaccine for world's leading infectious child killer. GAVI Alliance., http://www.gavialliance.org/media_centre/press_releases/2009_04_23_rwanda_pneumococco.php
28. PneumoADIP Surveillance and Research Report. Baltimore 2007, PneumoADIP.
29. Murray CJL, Lopez AD. The Global Burden of Disease, Vol. 1 of Global Burden of Disease and Injury Series. 1996, Cambridge, MA: Harvard University Press.
30. Initiative for Vaccine Research of WHO Department of Immunization, Vaccines and Biologicals of WHO: WHO Guide for Standardization of Economic Evaluations of Immunization Programmes. 2008, Geneva: World Health Organization, WHO/IVB/08.14.
31. Lucero MG, Williams G. Vaccine trial as "probe" to define the burden of pneumococcal pneumonia disease. Lancet 2005, 365:1113-1114. 10.1016/S0140-6736(05)71853-5, 15794951.
32. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due to bacterial meningitis among African children: a systematic literature review. BMC Medicine 2009, 7:47. 10.1186/1741-7015-7-47, 2759956, 19751516.
33. WHO/UNICEF Immunization Summary-A Statistical Reference Containing Data through 2007 (The 2009 Edition). WHO/UNICEF., http://www.childinfo.org/Immunization.htm
34. Knuf M, Habermehl P, Cimino C, Petersen G, Schmitt HJ. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants. Vaccine 2006, 24(22):4727-4736. 10.1016/j.vaccine.2006.03.032, 16616973.
35. Huebner RE, Mbelle N, Forrest B, Madore DV, Klugman KP. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatric Infectious Disease Journal 2002, 21(11):1004-1007. 10.1097/00006454-200211000-00006, 12442020.
36. Adegbola RA, Secka O, Lahai G, Lloyd-Evans N, Njie A, Usen S, Oluwalana C, Obaro S, Weber M, Corrah T, Mulholland K, McAdam K, Greenwood B, Milligan PJ. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005, 366(9480):144-50. 10.1016/S0140-6736(05)66788-8, 16005337.
37. Forgie IM, Campbell H, Lloyd-Evans N, Leinonen M, O'Neill KP, Saikku P, Whittle HC, Greenwood BM. Etiology of acute lower respiratory tract infections in children in a rural community in The Gambia. Pediatr Infect Dis J 1992, 11(6):466-473. 10.1097/00006454-199206000-00009, 1608684.
38. Forgie IM, O'Neill KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, Greenwood BM. Etiology of acute lower respiratory tract infections in Gambian children: I. Acute lower respiratory tract infection in infants presenting at the hospital. Pediatr Infect Dis J 1991, 10(1):33-41. 10.1097/00006454-199101000-00008, 1848364.
39. Forgie IM, O'Neill KP, Lloyd-Evans N, Leinonen M, Campbell H, Whittle HC, Greenwood BM. Etiology of acute lower respiratory tract infections in Gambian children: II. Acute lower respiratory tract infection in children ages one to nine years presenting at the hospital. Pediatr Infect Dis J 1991, 10(1):42-7. 10.1097/00006454-199101000-00009, 2003054.
40. WHO Global Burden of Hib and Pneumococcal Disease study. WHO., http://www.who.int/immunization_monitoring/burden/GDB_Hib_Sp_Results_Database.xls
41. Palmer A, Weber M, Bojang K, McKay T, Adegbola R. Acute Bacterial Meningitis in The Gambia: A Four-year Review of Paediatric Hospital Admissions. Journal of Tropical Pediatrics 1999, 45(1):51-53. 10.1093/tropej/45.1.51, 10191594.
42. Valenzuela MT, O'Loughlin R, De La Hoz F, Gomez E, Constenla D, Sinha A, Valencia JE, Flannery B, De Quadros CA. The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Rev Panam Salud Publica 2009, 25(3):270-9. 10.1590/S1020-49892009000300011, 19454155.
43. PneumoADIP Global cases and deaths pneumococcal invasive non-pneumonia non-meningitis (NPNM) syndromes in children under 5. The 6th International Symposium on Pneumococci and Pneumococcal Diseases, Reykjavik, Iceland. 2008, PneumoADIP., http://www.preventpneumo.org/documents/isppd6/RESEARCH_POSTER_2.5.pdf
44. O'Dempsey TJ, McArdle TF, Lloyd-Evans N, Baldeh I, Lawrence BE, Secka O, Greenwood B. Pneumococcal disease among children in a rural area of west Africa. Pediatr Infect Dis J 1996, 15(5):431-437. 10.1097/00006454-199605000-00010, 8724066.
45. Adegbola RA, Hill PC, Secka O, Ikumapayi UN, Lahai G, Greenwood BM, Corrah T. Serotype and antimicrobial susceptibility patterns in isolates of Streptococcus pneumoniae causing invasive disease in The Gambia 1996-2003. Tropical Medicine and International Health 2006, 11(7):1128-1135. 10.1111/j.1365-3156.2006.01652.x, 16827713.
46. Usen S, Adegbola R, Mulholland K, Jaffar S, Hilton S, Oparaugo A, Omosigho C, Lahai G, Corrah T, Palmer A, Schneider G, Weber M, Greenwood B. Epidemiology of invasive pneumococcal disease in the Western Region, The Gambia. Ped Infect Dis J 1998, 17(1):23-28. 10.1097/00006454-199801000-00006, 9469390.
47. Antonio M, Dada-Adegbola H, Biney E, Awine T, O'Callaghan J, Pfluger V, Enwere G, Okoko B, Oluwalana C, Vaughan A, Zaman SM, Pluschke G, Greenwood BM, Cutts F, Adegbola RA. Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect Dis 2008, 8(81). 10.1186/1471-2334-8-81, PMC2440749, 18547404.
48. WHO A new approach to planning for immunization-WHO-UNICEF guidelines for developing a comprehensive multi-year plan (cMYP). WHO., https://extranet.who.int/ifdb/Login.aspx?ReturnUrl=%2Fifdb%2FDefault.aspx
49. Tan-Torres Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murry CJL. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization 2003,
50. Ayieko P, Akumu A, Griffiths U. The economic burden of inpatient paediatric care: household and provider costs for treatment of pneumonia, malaria and meningitis. Cost Effectiveness and Resource Allocation 2009, 7:3. 10.1186/1478-7547-7-3, 2640355, 19161598.
51. Department of State for Health and Social Welfare: The Standard Drug Treatment Guidelines, Banjul. 2001,
52. Management Sciences for Health: International Drug Price Indicator Guide. 2008,
53. Gambia Bureau of Statistics: The Gambia multiple indicator cluster survey 2005/2006 report.
54. World Bank: Health and Poverty in the Gambia. Washington 2005,
55. Gambia Department of State for Health and Social Welfare: Public Expenditure Review. Banjul. 2001,
56. Bowman RJ, Soma OS, Alexander N, Milligan P, Rowley J, Faal H, Foster A, Bailey RL, Johnson GJ. Should trichiasis surgery be offered in the village? A community randomised trial of village vs. health centre-based surgery. Tropical Medicine and International Health 2000, 5(8):528-533. 10.1046/j.1365-3156.2000.00605.x, 10995093.
57. Ministry of Health and Social Welfare Directorate of Planning and Information of the Republic of the Gambia: National Health Management Information System Service Statistics Report 2008. February 2009. , http://www.bricksite.com/User_files/89d351d02f540e28fe7c12c56b04e6d3.pdf
58. Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004, 22:4203-4214. 10.1016/j.vaccine.2004.05.003, 15474710.
59. Claes C, Reinert RR, Schulenburg JG. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ 2009, 10:25-38. 10.1007/s10198-008-0098-1, 18379830.
60. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, . Active Bacterial Core Surveillance of the Emerging Infections Program Network Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746. 10.1056/NEJMoa022823, 12724479, Active Bacterial Core Surveillance of the Emerging Infections Program Network.
61. WB/GAVI WHO: Meeting Report-WHO Workshop on Standardization of Pneumococcal Opsonophagocytic Assay. Geneva. 2007, WB/GAVI., http://www.who.int/biologicals/publications/meetings/areas/vaccines/pneumococcal/OPA%20meeting%20report-%20FINAL_June07.pdf
62. WHO The World Health Report 2002. 2002, Reducing Risks, Promoting Healthy Life. Geneva, WHO.
63. Enwere G, Biney E, Cheung YB, Zaman SM, Okoko B, Oluwalana C, Vaughan A, Greenwood B, Adegbola R, Cutts FT. Epidemiologic and clinical characteristics of community-acquired invasive bacterial infections in children aged 2-29 months in The Gambia. Pediatr Infect Dis J 2006, 25(8):700-705. 10.1097/01.inf.0000226839.30925.a5, 16874169.
64. Goetghebuer T, West TE, Wermenbol V, Cadbury AL, Milligan P, Lloyd-Evans N, Adegbola RA, Mulholland EK, Greenwood BM, Weber MW. Outcome of meningitis caused by Streptococcus pneumoniae and Haemophilus influenzae tybe b in children in The Gambia. Tropical Medicine and International Health 2000, 5(3):207-213. 10.1046/j.1365-3156.2000.00535.x, 10747284.
65. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(9546):1495-1502. 10.1016/S0140-6736(06)69637-2, 17071283.
66. Center for Disease Control Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease, United States, 1998-2003. MMWR 2005, 54:893-897. Center for Disease Control.
67. Albrich WC, Madhi SA, Lafond KE, Klugman KP. Herd immunity after pneumococcal conjugate vaccination. Lancet 2007, 370:218-219. 10.1016/S0140-6736(07)61119-2, 17658389.
68. Kim SY, Salomon JA, Goldie SJ. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bulletin of the World Health Organization 2007, 85:833-842. 2636252, 18038073.
69. Akumu AO, English M, Scott JA, Griffiths UK. Economic evaluation of delivering Haemophilus influenzae type b vaccine in routine immunization services in Kenya. Bulletin of the World Health Organization 2007, 85:511-518. 10.2471/BLT.06.034686, 2636374,2636374, 17768499.
70. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:c2509. 10.1136/bmj.c2509, 20519267.
71. Chibuk TK, Robinson JL, Hartfield DS. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with Pneumococcal Conjugate Vaccine (PCV7). Eur J Pediatr 2010,
72. Health Protection Agency Current Epidemiology of Invasive Pneumococcal Disease (IPD). Health Protection Agency., http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/
73. Peters TR, Poehling KA. Invasive Pneumococcal Disease: The Target Is Moving. JAMA 2007, 297(16):1825-1826. 10.1001/jama.297.16.1825, 17456826.
74. WHO African Health Ministers to Introduce New Vaccine to Prevent Deadly Meningitis Epidemics. WHO., http://www.gavialliance.org/media_centre/press_releases/2008_09_04_WHO_pr_meningitis.php
75. Sendi PP, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001, 10:675-680. 10.1002/hec.639, 11747050.
76. Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ 2002, 11:23-31. 10.1002/hec.641, 11788979.